Effect of sulfasalazine use on the presence of Pneumocystis organisms in the lung among patients with rheumatoid arthritis: A test-negative design case–control study with PCR tests

References

• Mori S, Sugimoto M. Pneumocystis jirovecii infection: an emerging threat to patients with rheumatoid arthritis. Rheumatology. 2012;51:2120–30.
   PubMed Web of Science ®Google Scholar
• Amos RS. The history of the use of sulphasalazine in rheumatology. Br J Rheumatol. 1995;34:2–6.
   PubMedGoogle Scholar
• Wang J, Gigliotti F, Bhagwat SP, George TC, Wright TW. Immune modulation with sulfasalazine attenuates immunopathogenesis but enhances macrophage- mediated fungal clearance during Pneumocystis pneumonia. PLoS Pathog. 2010;6:59–60.
   Web of Science ®Google Scholar
• Mizushina K, Hirata A, Hayashi N, Takenaka S, Ito H, Ogura T, et al. Possible preventive effect of salazosulfapyridine against development of Pneumocystis pneumonia in methotrexate-receiving patients with rheumatoid arthritis. Mod Rheumatol. 2015;7595:1–8.
   Google Scholar
• Limper AH, Offord KP, Smith TF, Martin WJ. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis. 1989;140:1204–9.
   PubMed Web of Science ®Google Scholar
• Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine. 2013;31:2165–8.
   PubMed Web of Science ®Google Scholar
• Sullivan SG, Tchetgen EJT, Cowling BJ. Theoretical basis of the test-negative study design for assessment of influenza vaccine effectiveness. Am J Epidemiol. 2016;184:345–53.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy Steven M, Bloch DA, McShane DJ, Fries JF, et al. Revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569–81.
   PubMed Web of Science ®Google Scholar
• Harigai M, Koike R, Miyasaka N. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med. 2007;357:1874–6.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Sakai R, Koike R, Komano Y, Nanki T, Sakai F, et al. Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors. Mod Rheumatol. 2012;22:849–58.
   PubMed Web of Science ®Google Scholar
• Watanabe K, Sakai R, Koike R, Sakai F, Sugiyama H, Tanaka M, et al. Clinical characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case-control study of 17 patients. Mod Rheumatol. 2012;7595:1–5.
   Google Scholar
• Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.
   PubMed Web of Science ®Google Scholar
• Fillatre P, Decaux O, Jouneau S, Revest M, Gacouin A, Robert-Gangneux F, et al. Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients. Am J Med. 2014;127:1242.e11–e17.
   PubMed Web of Science ®Google Scholar
• Cruciani M, Marcati P, Malena M, Bosco O, Serpelloni G, Mengoli C. Meta-analysis of diagnostic procedures for Pneumocystis carinii pneumonia in HIV-1-infected patients. Eur Respir J. 2002;20:982–9.
   PubMed Web of Science ®Google Scholar
• Kato M, Tobino K, Fujimoto Y, Kobayashi I, Sugano K, Tokuda H, et al. Pneumocystis pneumonia induced by treatment with low-dose tacrolimus and methylprednisolone in a patient with rheumatoid arthritis: a case report. BMC Res Notes. 2013;6:498.
   PubMedGoogle Scholar
• Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:189–94.
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: Postmarketing surveillance report of the first 3,000 patients. Mod Rheumatol. 2012;22:498–508.
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis. 2011;70:2148–51.
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2011;21:343–51.
   PubMed Web of Science ®Google Scholar
• Ospina FE, Agualimpia A, Bonilla-Abadía F, Cañas CA, Tobón GJ. Pneumocystis jirovecii Pneumonia in a patient with rheumatoid arthritis treated with abatacept. Case Rep Rheumatol. 2014;2014:835050.
   PubMedGoogle Scholar
• Sato T, Inokuma S, Maezawa R, Nakayama H, Hamasaki K, Miwa Y, et al. Clinical characteristics of Pneumocystis carinii pneumonia in patients with connective tissue diseases. Mod Rheumatol. 2005;15:191–7.
   PubMedGoogle Scholar
• Heinze G, Schemper M. A solution to the problem of separation in logistic regression. Statist Med. 2002;21:2409–19.
   PubMed Web of Science ®Google Scholar
• Vargas SL, Ponce CA, Gigliotti F, Ulloa AV, Prieto S, Muñoz MP, et al. Transmission of Pneumocystis carinii DNA from a patient with P. carinii Pneumonia to immunocompetent contact health care workers. J Clin Microbiol. 2000;38:1536–8.
   PubMed Web of Science ®Google Scholar
• Miller RF, Ambrose HE, Wakefield AE. Pneumocystis carinii f. sp. hominis DNA in immunocompetent health care workers in contact with patients with P. carinii pneumonia. J Clin Microbiol. 2001;39:3877–82.
   PubMed Web of Science ®Google Scholar
• Choukri F, Menotti J, Sarfati C, Lucet J, Nevez G, Garin YJF, et al. Quantification and spread of Pneumocystis jirovecii in the surrounding air of patients with Pneumocystis Pneumonia. Clin Infect Dis. 2010;51:259–65.
   PubMed Web of Science ®Google Scholar
• Mori S, Cho I, Sugimoto M. A followup study of asymptomatic carriers of Pneumocystis jiroveci during immunosuppressive therapy for rheumatoid arthritis. J Rheumatol. 2009;36:1600–5.
   PubMed Web of Science ®Google Scholar
• Thomas CF, Limper AH. Pneumocystis Pneumonia. N Engl J Med. 2004;350:2487–98.
   PubMed Web of Science ®Google Scholar
• Komano Y, Harigai M, Koike R, Sugiyama H, Ogawa J, Saito K, et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum. 2009;61:305–12.
   PubMed Web of Science ®Google Scholar
• Morris A, Wei K, Afshar K, Huang L. Epidemiology and clinical significance of Pneumocystis colonization. J Infect Dis. 2008;197:10–7.
   PubMed Web of Science ®Google Scholar
• Gutiérrez S, Morilla R, León JA, Martín-Garrido I, Rivero L, Friaza V, et al. High prevalence of Pneumocystis jiroveci colonization among young HIV-infected patients. J Adolesc Heal. 2011;48:103–5.
   PubMed Web of Science ®Google Scholar
• Albert A, Anderson JA. On the existence of maximum likelihood estimates in logistic regression models. Biometrika 1984;71:1–10.
   Web of Science ®Google Scholar